Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Thirty-eight surgical trainees from the Oxford and Severn Deaneries attended the first Bristol Oxford Surgical Trials Course (BOSTiC), a joint initiative between the Oxford Surgical Intervention Trials Unit (SITU) and the Bristol Surgical Trials Centre (BSTC).

 Thirty-eight surgical trainees from the Oxford and Severn Deaneries attended the first Bristol Oxford Surgical Trials Course (BOSTiC), a joint initiative between the Oxford Surgical Intervention Trials Unit (SITU) and the Bristol Surgical Trials Centre (BSTC). Supported by both the Severn and Oxford Deaneries, along with the Royal College of Surgeons (RCS), BOSTiC is directed by Professor Jane Blazeby (BSTC) and Professor David Beard (SITU), with Professor Jonathan Cook (SITU) and Mr Angus McNair (BSTC) forming the rest of the core faculty.

The aim of BOSTiC was to provide surgical trainees with an overview of what it takes to deliver a successful surgical trial, from the formation of an idea through to delivery of the trial. No previous experience in surgical trials was necessary as BOSTiC covered all of the basics as well as highlighting specific topics such as the research question, design and outcome measurement and statistical analysis.

It was decided from the outset that BOSTiC should be delivered in a way that was as interactive as possible, giving everybody the chance to ask questions at any time during the teaching sessions The result was a fertile mix of debate/discussion on many aspects of surgical trials, often into new territory. It was widely agreed that this style of learning was the most appropriate and beneficial for the delegates  It also led to some interesting debates/differences of opinion amongst the faculty!

The presentations throughout the course were varied and stimulating. Highlights included Professor Andrew Carr speaking about the role that placebo can play in surgical trials, Dr Chris Rogers covering statistical issues, Professor Freddie Hamdy telling the story of the ProtecT trial, and Professor Matthew Costa presenting a trial to the group in a ‘reverse dragon’s den’ style. Attendees noted the ‘inspirational’ nature of some of the talks, and enjoyed their opportunity to present a trial that they had been working on in groups at the end of the course.

Whilst the course was intense by its very nature, participants overwhelmingly agreed that having a three day continuous course was the most productive way of running such an event. A course dinner on the first evening provided attendees with a great opportunity to get to know each other; with several commenting that it was rare for them to mix so much with those other specialties.

The feedback that we received for the BOSTiC course was very positive, and we hope that the trainees who took part are inspired to get involved in surgical trials in the future, and potentially become the next generation of surgical trialists. BOSTiC will run again in 2016, and will be held at the Bristol Surgical Trials Centre.

Similar stories

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.

Study reveals new evidence on rare blood-clotting condition after covid-19 vaccination

Researchers from NDORMS at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.

NDORMS contributes to new UK research to tackle monkeypox outbreak

The UK’s efforts to tackle the monkeypox outbreak will receive a huge boost with the creation of a new research consortium and a new study to study vaccine effectiveness.

World Osteoporosis Day 2022

A bone-healthy lifestyle is vital for strong bones and a mobile, fracture-free future. On World Osteoporosis Day, we are sharing advice from the International Osteoporosis Foundation (IOF), on putting your bone health first.

Mathematician boosts data science research at the Kennedy Institute

Welcome to Yang Luo who has joined the Kennedy Institute as the Principal Investigator of the Luo Group. Her lab is leading the investigation into how genetic variations contribute to diseases of the immune system.